Cargando…
Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028131/ https://www.ncbi.nlm.nih.gov/pubmed/36959801 http://dx.doi.org/10.3389/fonc.2023.1119744 |
_version_ | 1784909875799654400 |
---|---|
author | Xu, Yuyan Cai, Jianpeng Zhong, Kaihang Wen, Yaohong Cai, Lei He, Guolin Liao, Hangyu Zhang, Cheng Fu, Shunjun Chen, Tingting Cai, Jinping Zhong, Xuefeng Chen, Chunzhu Huang, Mengli Cheng, Yuan Pan, Mingxin |
author_facet | Xu, Yuyan Cai, Jianpeng Zhong, Kaihang Wen, Yaohong Cai, Lei He, Guolin Liao, Hangyu Zhang, Cheng Fu, Shunjun Chen, Tingting Cai, Jinping Zhong, Xuefeng Chen, Chunzhu Huang, Mengli Cheng, Yuan Pan, Mingxin |
author_sort | Xu, Yuyan |
collection | PubMed |
description | BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC). METHODS: Here, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection. RESULTS: A total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in TP53 (45.1%), LRP1B (20.2%), TERT (20.2%), FAT1 (16.2%), and CTNNB1 (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months vs. NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002). CONCLUSIONS: We successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC. |
format | Online Article Text |
id | pubmed-10028131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100281312023-03-22 Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection Xu, Yuyan Cai, Jianpeng Zhong, Kaihang Wen, Yaohong Cai, Lei He, Guolin Liao, Hangyu Zhang, Cheng Fu, Shunjun Chen, Tingting Cai, Jinping Zhong, Xuefeng Chen, Chunzhu Huang, Mengli Cheng, Yuan Pan, Mingxin Front Oncol Oncology BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC). METHODS: Here, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection. RESULTS: A total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in TP53 (45.1%), LRP1B (20.2%), TERT (20.2%), FAT1 (16.2%), and CTNNB1 (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months vs. NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002). CONCLUSIONS: We successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028131/ /pubmed/36959801 http://dx.doi.org/10.3389/fonc.2023.1119744 Text en Copyright © 2023 Xu, Cai, Zhong, Wen, Cai, He, Liao, Zhang, Fu, Chen, Cai, Zhong, Chen, Huang, Cheng and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Yuyan Cai, Jianpeng Zhong, Kaihang Wen, Yaohong Cai, Lei He, Guolin Liao, Hangyu Zhang, Cheng Fu, Shunjun Chen, Tingting Cai, Jinping Zhong, Xuefeng Chen, Chunzhu Huang, Mengli Cheng, Yuan Pan, Mingxin Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title | Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title_full | Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title_fullStr | Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title_full_unstemmed | Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title_short | Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
title_sort | plasma-only circulating tumor dna analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028131/ https://www.ncbi.nlm.nih.gov/pubmed/36959801 http://dx.doi.org/10.3389/fonc.2023.1119744 |
work_keys_str_mv | AT xuyuyan plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT caijianpeng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT zhongkaihang plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT wenyaohong plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT cailei plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT heguolin plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT liaohangyu plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT zhangcheng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT fushunjun plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT chentingting plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT caijinping plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT zhongxuefeng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT chenchunzhu plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT huangmengli plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT chengyuan plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection AT panmingxin plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection |